Morgan Stanley’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $57.6M | Sell |
4,637,185
-180,914
| -4% | -$2.43M | ﹤0.01% | 1953 |
|
|
2025
Q4 | $60.7M | Buy |
4,818,099
+1,315,018
| +38% | +$15M | ﹤0.01% | 1903 |
|
|
2025
Q3 | $35.1M | Buy |
3,503,081
+1,005,848
| +40% | +$9.03M | ﹤0.01% | 2337 |
|
|
2025
Q2 | $20.2M | Buy |
2,497,233
+876,232
| +54% | +$6.61M | ﹤0.01% | 2795 |
|
|
2025
Q1 | $13.6M | Buy |
1,621,001
+133,240
| +9% | +$1.11M | ﹤0.01% | 3065 |
|
|
2024
Q4 | $11.8M | Buy |
1,487,761
+242,585
| +19% | +$2.04M | ﹤0.01% | 3270 |
|
|
2024
Q3 | $10.4M | Buy |
1,245,176
+209,571
| +20% | +$1.64M | ﹤0.01% | 3406 |
|
|
2024
Q2 | $6.58M | Buy |
1,035,605
+79,643
| +8% | +$506K | ﹤0.01% | 3669 |
|
|
2024
Q1 | $5.79M | Buy |
955,962
+71,376
| +8% | +$402K | ﹤0.01% | 3801 |
|
|
2023
Q4 | $5.37M | Buy |
884,586
+508,410
| +135% | +$2.26M | ﹤0.01% | 4333 |
|
|
2023
Q3 | $1.59M | Sell |
376,176
-59,349
| -14% | -$221K | ﹤0.01% | 4530 |
|
|
2023
Q2 | $1.35M | Buy |
435,525
+53,037
| +14% | +$113K | ﹤0.01% | 4652 |
|
|
2023
Q1 | $532K | Sell |
382,488
-3,838,510
| -91% | -$7.64M | ﹤0.01% | 5219 |
|
|
2022
Q4 | $8.4M | Buy |
4,220,998
+3,813,489
| +936% | +$8.55M | ﹤0.01% | 3247 |
|
|
2022
Q3 | $823K | Sell |
407,509
-54,911
| -12% | -$154K | ﹤0.01% | 4993 |
|
|
2022
Q2 | $1.47M | Buy |
462,420
+39,691
| +9% | +$144K | ﹤0.01% | 4754 |
|
|
2022
Q1 | $1.76M | Buy |
422,729
+8,649
| +2% | +$38.3K | ﹤0.01% | 4608 |
|
|
2021
Q4 | $1.98M | Buy |
414,080
+99,697
| +32% | +$497K | ﹤0.01% | 4588 |
|
|
2021
Q3 | $1.68M | Buy |
314,383
+147,054
| +88% | +$740K | ﹤0.01% | 4710 |
|
|
2021
Q2 | $856K | Buy |
167,329
+13,005
| +8% | +$73.9K | ﹤0.01% | 5175 |
|
|
2021
Q1 | $1.04M | Sell |
154,324
-89,736
| -37% | -$497K | ﹤0.01% | 4711 |
|
|
2020
Q4 | $1.12M | Sell |
244,060
-6,978
| -3% | -$30.9K | ﹤0.01% | 4593 |
|
|
2020
Q3 | $974K | Buy |
251,038
+163,848
| +188% | +$701K | ﹤0.01% | 4230 |
|
|
2020
Q2 | $415K | Sell |
87,190
-8,905
| -9% | -$36.7K | ﹤0.01% | 4696 |
|
|
2020
Q1 | $334K | Sell |
96,095
-217,288
| -69% | -$920K | ﹤0.01% | 4601 |
|
|
2019
Q4 | $1.51M | Sell |
313,383
-1,717,078
| -85% | -$5.97M | ﹤0.01% | 4243 |
|
|
2019
Q3 | $5.89M | Buy |
2,030,461
+1,994,724
| +5,582% | +$6.96M | ﹤0.01% | 2685 |
|
|
2019
Q2 | $256K | Buy |
35,737
+7,390
| +26% | +$75.6K | ﹤0.01% | 4924 |
|
|
2019
Q1 | $402K | Sell |
28,347
-115,791
| -80% | -$1.53M | ﹤0.01% | 4690 |
|
|
2018
Q4 | $1.95M | Sell |
144,138
-133,934
| -48% | -$2.41M | ﹤0.01% | 3792 |
|
|
2018
Q3 | $6.17M | Sell |
278,072
-40,128
| -13% | -$844K | ﹤0.01% | 2960 |
|
|
2018
Q2 | $5.22M | Buy |
+318,200
| New | +$5.58M | ﹤0.01% | 3091 |
|
Other funds holding AMRX
TGA
VPM
RCMNY
VCM
N
Morgan Stanley's AMRX Position: Q1 2026 in Review
Morgan Stanley reduced its Amneal Pharmaceuticals (AMRX) stake by 3.8% in Q1 2026, selling an estimated $2.43M and leaving 4,637,185 shares worth $57.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1953.
Morgan Stanley first reported a position in AMRX in Q2 2018 and has held it in 32 quarters since. The position peaked at $60.7M in Q4 2025. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.
- Morgan Stanley held 4,637,185 shares of Amneal Pharmaceuticals worth $57.6M as of Q1 2026.
- Morgan Stanley sold 180,914 Amneal Pharmaceuticals shares in Q1 2026, an estimated $2.43M.
- Amneal Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #1953 holding.
- Morgan Stanley first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
- Morgan Stanley's Amneal Pharmaceuticals position peaked at $60.7M in Q4 2025.
- 316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.